Q-omics provides the consensus-scored CCDC60 profile across patient tissues and cancer cell-line models. CCDC60 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CCDC60 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CCDC60 RNA expression shows 14,444 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where CCDC60 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC60 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC60 survival associations across molecular data types. CCDC60 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC60 RNA expression–survival associations across cancer types. High CCDC60 expression shows unfavorable associations in LUAD and ACC, but favorable associations in HNSC, COAD, KICH and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for CCDC60 RNA expression.
This table summarizes CCDC60 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC60. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC60 shows lower tumor expression in HNSC, BLCA, LUSC, LUAD and UCEC and higher tumor expression in BRCA. The HNSC box plot shows higher CCDC60 RNA expression in normal versus tumor tissue (log2 FC = −1.048, t-test p < 0.001).
This table shows molecular features associated with CCDC60 in patient tissues and cancer cell lines. In patient samples, CCDC60 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC60 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_SCLC.
